Impel NeuroPharma to Host Virtual Key Opinion Leader Event on August 6, 2021
Impel NeuroPharma (NASDAQ: IMPL) will host a virtual key opinion leader (KOL) event on August 6, 2021, at 1:00 PM ET, to discuss the treatment landscape for acute migraines post-triptan failure.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Impel NeuroPharma (NASDAQ: IMPL) will host a virtual key opinion leader (KOL) event on August 6, 2021, at 1:00 PM ET, to discuss the treatment landscape for acute migraines post-triptan failure. The event includes presentations from leading experts on non-oral migraine therapies and shares results from the STOP301 trial for TRUDHESA™, Impel's lead product candidate. A live webcast of the discussion can be accessed on Impel's website, with a replay available afterwards.
Details
News Market Reaction – IMPL
The recorded move for IMPL in the trading session of this news was +9.58%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, July 29, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that it will host a virtual key opinion leader (KOL) event to review the post triptan failure landscape and new options for the treatment of acute migraine. In addition, the program will cover the role of non-oral acute migraine therapies, including the history of use of dihydroergotamine (DHE), the STOP301 trial results for Impel’s lead product candidate TRUDHESA™ and commercial insights and opportunities in the acute migraine market. The event will take place on Friday, August 6, 2021 at 1:00pm ET.
The event will feature presentations from guest speakers Dr. Wade Cooper, Director of Headache and Neuropathic Pain at the University of Michigan School of Medicine, Dr. Stewart Tepper, Director of Dartmouth Headache Center at the Geisel School of Medicine, Dr. Nada Hindiyeh, Assistant Professor of neurology and neurological systems at Stanford Medical School and Impel NeuroPharma management.
A live webcast of the event will be available on the Investors section of the Impel NeuroPharma website at https://investors.impelnp.com/. A replay of the webcast and accompanying slides will be available on the Impel NeuroPharma website following the event.
About Impel NeuroPharma
Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.
Investor Relations:
Christina Tartaglia
Stern Investor Relations
Phone: (1) 212-362-1200
Email: christina.tartaglia@sternir.com
Media Relations:
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 201-723-5805
Email: mweible@elixirhealthpr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.